AUTHORS
Ashlyn O'Leary, MD, Ashwin Sunderraj, M.D.2, Ali Haider Mohamedi, MD3, Anika Patel, MD4, Shining Yang, MA5, Julia M. Anderson, BS, MS6, Gabino Escalada, MS7, Alejandro Marinos Velarde, MD8, Vivian Irizarry Gatell, MD9, Clayton Jackson, MD10, Shukaib Arslan11, Stephen Chung, MD12, Robert Collins, MD13, Aimaz Afrough, MD14, Yazan F. Madanat, MD15
AFFILIATIONS
1 UT Southwestern, Dallas, Texas, United States
2 UT Southwestern, Dallas, Texas, United States
3 UT Southwestern, Dallas, Texas, United States
4 UT Southwestern, Dallas, Texas, United States
5 UT Southwestern, Dallas, Texas, United States
6 UT Southwestern, Dallas, Texas, United States
7 UT Southwestern, Dallas, Texas, United States
8 UT Southwestern, Dallas, Texas, United States
9 UT Southwestern, Dallas, Texas, United States
10 UT Southwestern, Dallas, Texas, United States
11 UT Southwestern, Dallas, Texas, United States
12 UT Southwestern, Dallas, Texas, United States
13 UT Southwestern, Dallas, Texas, United States
14 UT Southwestern, Dallas, Texas, United States
15 UT Southwestern, Dallas, Texas, United States
ABSTRACT
Background: Myeloid neoplasms (MN), including clonal cytopenia of undetermined significance (CCUS), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML), comprise a heterogeneous group. While these diseases have been considered biologically distinct from plasma cell dyscrasias (PCD) [monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM)], increasing evidence suggests potential overlap in their pathogenesis through shared clonal processes, genetic susceptibility, or treatment-related mechanisms. The coexistence of MN with PCD may influence disease presentation, therapeutic decision-making, and clinical outcomes, yet these patients remain understudied. We evaluated baseline disease characteristics, treatment patterns, and survival outcomes in patients with MN alone compared with those with concurrent PCD.
Methods: We retrospectively identified patients diagnosed with CCUS, MDS, or AML with concurrent PCD between 2010 and 2025 and compared them with patients with the corresponding MN alone. Clinical and disease characteristics, treatment patterns, and outcomes were compared between cohorts. Patients were grouped into four cohorts: 1 CCUS/MDS alone; 2 AML alone; 3 CCUS/MDS with PCD; and 4. AML with PCD. Comparisons were performed between cohorts 1 vs. 3 and 2 vs. 4. Categorical and continuous variables were compared using Fisher's exact and Mann–Whitney U tests, respectively. Overall survival (OS) was estimated using Kaplan–Meier method and compared using log-rank test.
Results: A total of 1,078 patients were identified, including 420 (39.0%) with MDS alone, 571 (53.0%) with AML alone, 64 (5.9%) with MDS-PCD, and 23 (2.1%) with AML-PCD. Median follow-up duration was 50.3 (46.7-56.3) months.
Among patients with MDS, those with MDS-PCD were older (72.0 vs. 69.7 years, P = 0.04), whereas sex, race, and ethnicity were similar between cohorts. MDS-PCD had significantly higher hemoglobin levels and absolute neutrophil counts at diagnosis (P = 0.046 and P = 0.027, respectively), while platelet counts were similar. They also had a lower median number of mutations than MDS alone (2.0 [1.0, 3.0] vs. 3.0 [1.0, 4.0] respectively, P = 0.017). Among patients with PCD, 45.3% had MGUS, 12.5% smoldering MM, and 42.2% MM; 37.5% of patients with MM received MM-directed therapy and 21.9% underwent autologous transplantation. Most patients (51.6%) with PCD did not receive MDS-directed therapy, whereas 17.2% received hypomethylating agent-based therapy. The median number of MDS treatment lines was 0.0 (0.0–3.0). Allogeneic transplantation was performed in 9.4% versus 14.8% of patients (P = 0.044). There was a significantly shorter OS among patients with MDS alone than those with MDS and concurrent PCD (median 37.9 vs. 118.7 months, respectively, P = 0.041).
Among patients with AML, age, sex, race, and ethnicity were similar between cohorts. Blood counts and mutational burden were also similar, with a median of 3 mutations in both groups (P = 0.963). Among patients with concurrent PCD, 39.1% had complex cytogenetics, 13.0% had normal cytogenetics, and 39.1% had other cytogenetic abnormalities. Among patients with PCD, the majority (65.2%) had MM, 26.1% had MGUS and 8.7% smoldering MM; 60.9% of patients with MM received MM-directed therapy and 30.4% underwent autologous transplantation. Treatment data were available for 17 patients with PCD. 58.8% received lower-intensity HMA-based therapy and 41.2% received intensive therapy. The median number of AML treatment lines was 2.0 (1.0–4.0). Allogeneic transplantation rates were similar between cohorts (26.1% vs. 25.0%, P = 1.000). A trend toward shorter OS in AML-PCD versus AML alone was observed (median 8.1 months vs. 25.4 months respectively, P = 0.086).
Conclusions: Concurrent plasma cell dyscrasias define clinically distinct subsets of patients with myeloid neoplasms, with divergent clinical phenotypes, treatment patterns, and survival in MDS and AML. Patients with MDS-PCD demonstrated significantly prolonged overall survival despite lower rates of allogeneic transplantation, whereas AML-PCD showed a trend toward inferior survival despite similar transplantation rates. These contrasting findings raise the possibility of distinct biological interactions between plasma cell and myeloid clones across disease subtypes and support future studies investigating shared clonal architecture through genomic sequencing of putative common progenitor cells.
DISCLOSURES
Ashlyn O'Leary, MD: No relevant conflicts of interest to declare.